Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. - Wikidata - wikimedia - TriplyDB

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

http://www.wikidata.org/entity/Q42104395

about

An Optimized Lock Solution Containing Micafungin, Ethanol and Doxycycline Inhibits Candida albicans and Mixed C. albicans - Staphyloccoccus aureus Biofilms Epidemiology of invasive candidiasis: a persistent public health problem Safety and pharmacokinetics of repeat-dose micafungin in young infants.Micafungin use in children.Micafungin in the treatment of invasive candidiasis and invasive aspergillosis Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study.Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction.Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006 Developments in the treatment of candidiasis: more choices and new challenges.Micafungin: a new echinocandin antifungal.The echinocandins.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.Micafungin for the prophylaxis and treatment of Candida infections.Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.Safety of micafungin in infants: insights into optimal dosing.Antifungal drug resistance among Candida species: mechanisms and clinical impact.Echinocandin Resistance in Candida Species: a Review of Recent Developments.Genetic Drivers of Multidrug Resistance in Candida glabrata.Echinocandins in antifungal pharmacotherapy.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.Echinocandins: A ray of hope in antifungal drug therapy Oral Candida in Patients with Fixed Orthodontic Appliance: In Vitro Combination Therapy.Antifungal resistance: current trends and future strategies to combat.In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.Occurrence of killer Candida glabrata clinical isolates.Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species.Potent Synergy between Spirocyclic Pyrrolidinoindolinones and Fluconazole against Candida albicans.Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis."De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany.Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection.Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

P2860

Q28552679-38EB30EA-9691-409A-AE52-6B76BC4E8B36 Q29616758-4B8B1D75-B631-429F-A6B9-A8D91AA415D7 Q30433612-3A8B994F-C710-476B-8EA0-A5D4CBC8E7DB Q33397111-2171139A-1B32-4469-A554-1E8BB2E31AE3 Q35026516-081DCD24-29DF-409E-BB70-E119E6CFDD7D Q35073614-7DBB23DE-3CF8-4A4D-BC5F-7494B583F0B2 Q35867789-D3A5ECF3-823E-432B-BFA9-A02412445134 Q35899223-DACE52C4-25E0-491D-BC6E-752D6A5C4F84 Q36004967-4E8C57A9-55D8-48B3-ABFC-DCB5F95EC347 Q36424929-95DDA28A-5672-43AC-9B52-CC02D9481867 Q36623050-4C77DD8D-375B-460D-9B3E-B59C266E8AD1 Q36693843-E591A526-7498-47C3-9CB8-3D22A7F0671E Q36742397-23147D91-76E0-4F9B-8572-54462F84218F Q36828156-CDA43430-5014-4BF2-B636-49F2C737C432 Q36845482-5CDACC1E-CCD0-427E-985A-33DAFCD916DE Q36867925-C8E25C81-7E6A-40E0-9D54-D5C0DECFA01A Q36895679-D02FF9D8-B74B-4750-97F0-74F6E222040E Q37124868-F8A4E186-560F-49BF-97A1-CEED5DB41BF6 Q37283043-F2637B86-0A9A-40B6-AF3D-F4538AF49F64 Q37443139-ED5B9683-C813-4328-925E-C07B2882F417 Q37827883-FFF7DCBD-774A-4E71-990F-180E0AFDFCB6 Q38511946-64FC3F75-F2AB-4CCF-B60B-F4225DB7A16A Q38988521-99D685FA-0DCB-4A7E-A528-3C3F892903E7 Q39065051-D7C27D8A-8589-47D7-A54A-AA0EBFD986F3 Q39458862-7139D1C6-D672-418F-ACCB-F31705FAF607 Q39701953-D20CC70C-A716-490A-AD77-E0535DA94C65 Q40939764-D728A478-CC5B-4236-830B-B68C13C85FE1 Q41066834-0F40D57F-0164-4BF8-917C-7BBBA260FBFA Q41072330-6DA451F4-2CDE-41F1-8911-054C7829CC80 Q41632930-903697DD-1A0C-435B-82EC-700F2CE3037C Q41810114-ED1D2ADF-5557-4727-948E-53D27DF1A540 Q41995489-B778F058-B872-4480-B05F-9BD5AD1923F8 Q42035300-D6620DFC-4F91-4091-A24F-D673DD1130A2 Q42111171-024077F3-AD04-41D8-BFC7-0B8F7D25007D Q42824165-E342ACA5-0A6A-4AF3-BA74-E986352E894C Q44685491-514B8516-63A2-48DB-B19E-1868AA818F3A Q47102441-F1763109-0B23-422C-B911-34F316FB9CCF Q47206195-1CFF3FFB-5A03-40F4-8E04-69559D5BA26A Q51166051-45AB27CF-C6AF-465C-89E1-9D23534F97F4 Q56934885-4C9B9DD4-7210-42FF-8EEA-440822C72140

P2860

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

http://www.wikidata.org/entity/Q42104395

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Activities of micafungin again ...... onazole-resistant Candida spp.

@en

Activities of micafungin again ...... onazole-resistant Candida spp.

@nl

type

label

Activities of micafungin again ...... onazole-resistant Candida spp.

@en

Activities of micafungin again ...... onazole-resistant Candida spp.

@nl

prefLabel

Activities of micafungin again ...... onazole-resistant Candida spp.

@en

Activities of micafungin again ...... onazole-resistant Candida spp.

@nl

P1433

Q42104395-E0303759-E233-4F23-9D89-A9E4ACE1A7C3

P1476

Q42104395-90940872-F934-4B76-AA78-DCE8207EB3FB

P2093

Q42104395-3F47E9ED-FEB2-4C22-AAE8-8DCF61B347C3

Q42104395-B92904A8-4D4E-43C9-AE0E-9B2C084B5EE2

Q42104395-C55F1E58-7733-4EE6-BA74-410CE9E88546

Q42104395-D0262A1A-C57D-4784-B8A5-9401E269B8B6

Q42104395-E2AFA4D7-D577-481C-959F-04D17E950BB2

P2860

Q42104395-1C76BFFB-BC52-4533-A326-808C64E299BD

Q42104395-29222E2D-FB7A-4638-83E7-F7053D29A069

Q42104395-37001281-ECC6-41E6-9E08-1BB73D2C942B

Q42104395-38A3EE23-8C75-48BF-A0E0-3D96226DABE3

Q42104395-4D1E3DA7-6C60-4663-B89F-D8F09ED3FDAF

Q42104395-6D096C36-5356-4578-AF24-0EA5918815D9

Q42104395-72E5BF06-B29B-4583-8C0A-73503232B494

Q42104395-A3C0C5D9-A3A3-47B3-BE26-07FD4FAF3591

Q42104395-A4CF2AED-EE99-48A3-820F-D09095A439E6

Q42104395-AC96281E-CA7E-4E9B-8F9A-51767C614E3C

P304

Q42104395-30B1AA41-71FD-4AAD-A565-62A601682974

P31

Q42104395-F2B3C272-3264-42C3-AF20-3AC5A9D1EADC

P356

Q42104395-C975127F-E47A-44AA-9C37-8258CE10CE2A

P407

Q42104395-05E5D6AD-91A4-45B6-B434-31A8F1D5DAA1

P433

Q42104395-C9C4DF2C-D477-4BB8-95E9-14A756D2FB10

P478

Q42104395-DDD58200-0171-4A52-AABD-DE7ADEFDA69B

P50

Q42104395-B9659FBF-01F4-4B27-86E7-5A4E69500175

P577

Q42104395-8661F6DA-ECCD-4C71-BA95-41EE86EE83A2

P698

Q42104395-94FF7374-2EC8-4B24-9D41-15564144782C

P932

Q42104395-B3BFCF23-61A6-42A5-8DB9-DBB37417D9C8

P356

JCM.44.2.324-326.2006

P1433

Journal of Clinical Microbiology

P1476

Activities of micafungin again ...... conazole-resistant Candida spp

@en

P2093

Boyken L

http://www.w3.org/2001/XMLSchema#string

Hollis RJ

http://www.w3.org/2001/XMLSchema#string

Messer SA

http://www.w3.org/2001/XMLSchema#string

Pfaller MA

http://www.w3.org/2001/XMLSchema#string

Tendolkar S

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

Echinocandin antifungal drugs

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Par

Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

Pharmacokinetics/pharmacodynamics of echinocandins.

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

P304

324-326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.44.2.324-326.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Diekema

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16455878

http://www.w3.org/2001/XMLSchema#string

P932

1392702

http://www.w3.org/2001/XMLSchema#string